Investigation of the Expression Levels of <scp>miR</scp> ‐383, <scp>miR</scp> ‐381, and <scp>miR</scp> ‐141 <scp>miRNAs</scp> as Diagnostic Biomarkers in Acute Myeloid Leukemia

BACKGROUND: Acute myeloid leukemia (AML) is a clonal illness that is different in both medical and biological traits. Nonetheless, the genetic basis of this malignancy remains inadequately elucidated. MicroRNAs (miRNAs) are small noncoding RNAs that modify the expression of target mRNAs at both transcriptional and translational levels. In the past decade, miRNAs have evolved a unique mechanism in gene regulation, exhibiting varying expression throughout myeloid differentiation. This investigation examines the serum levels of miR-383, miR-381, and miR-141 in AML and evaluates their diagnostic potential. METHODS: technique and normalized by U6. Diagnostic performance was assessed by the ROC curve analysis. RESULTS: MiR-383 was significantly upregulated (p = 0.0001), while miR-381 and miR-141 were downregulated (p = 0.0002 and p = 0.0004, respectively) in AML patients. In addition, a considerable correlation was demonstrated between the expression levels of miR-381 and subtype (p = 0.02). In addition, the expression levels of miR-141 and miR-381 were positively correlated in AML patients (r = 0.99, p ≤ 0.0001). The ROC analysis revealed strong potential of miR-383 (AUC 0.87, 95% CI: 0.82-0.91), miR-381 (AUC 0.71, 95% CI: 064-0.78), and miR-141 (AUC 0.84, 95% CI: 0.79-0.89) as promising diagnostic biomarkers. CONCLUSION: These miRNAs display distinct serum expression levels in AML, with miR-383, miR-381, and miR-141 demonstrating potential as diagnostic biomarkers, necessitating additional confirmation.